Skip to content

S2024-01

Clinical trial of S2024-01 in subjects with de novo coronary lesions in small vessels (SV) or in-stent restenosis (ISR) lesions - S2024-01

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2032250301
Enrollment
180
Registered
2025-08-20
Start date
2025-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with De Novo SV lesions or ISR lesions

Interventions

PCI
PCI,DCB

Sponsors

Nakamura Masato
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients aged 20 years or older. Patients who understand the requirements and procedures of the present clinical trial and have provided written informed consent prior to undergoing any study specific examinations or procedures. Patients who are indicated for PCI. Patients diagnosed with either stable angina or unstable angina. In the case of stable angina, patients must meet at least one of the following criteria 1. A stenotic lesion with over 90 percent diameter narrowing. 2. A stenotic lesion considered to be the cause of stable effort angina, provided that no other significant stenotic lesions are present. 3. A stenotic lesion confirmed to be the cause of ischemia based on functional ischemia assessment. Patients who may be eligible for CABG. Note, In addition, angiographic inclusion criteria are also defined.

Exclusion criteria

Exclusion criteria: Patients who have experienced an acute myocardial infarction within 72 hours prior to the study procedure. Patients with cardiogenic shock, hemodynamic instability requiring inotropic support or mechanical circulatory assistance, refractory ventricular arrhythmias, or ongoing refractory angina. Patients with severe left ventricular dysfunction, defined as a left ventricular ejection fraction of less than 30 percent. Patients with a history of organ transplantation or those scheduled to undergo organ transplantation. Patients who have received or are scheduled to receive cancer chemotherapy within 30 days before or after the study procedure. Patients with renal failure, defined as a serum creatinine level exceeding 2.0 mg per dL, or those undergoing dialysis or chronic immunosuppressive therapy. Note, in addition, angiographic exclusion criteria are also defined.

Design outcomes

Primary

MeasureTime frame
The incidence of TLF at 6 months after the index procedure

Countries

Japan, non

Contacts

Public ContactKumiko Sato

Clinical Operation

kumiko.sato01@cordis.com+81-3-6256-9125

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026